Filing Flows › Traws Pharma (TRAW) › Q4 2024
Traws Pharma (TRAW) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Traws Pharma (TRAW) reported revenue of $56K for the fourth quarter 2024 (Q4 2024), 0% from a year earlier and -2% from the quarter before.
Traws Pharma, Q4 2024: revenue $56K (0% year over year), net loss $29.9M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $56K | -2% | 0% |
| Operating profit | −$5.3M | — | — |
| Net earnings | −$29.9M | — | — |
| Operating cash flow | −$4.0M | — | — |
What changed
Revenue was $56K in Q4 2024, roughly flat year over year and down 2% from the previous quarter.
Operating costs exceeded revenue by $5.3M, an operating margin of -9425.0%. Total costs grew 18% against flat revenue. The fastest-growing cost line was General & admin (+67%). The quarter ended with a net loss of $29.9M, wider than the previous quarter's $8.5M loss. Net interest and other expense of $24.6M was the main reason.
Operating cash flow was −$4.0M. Non-cash charges added back $2K of depreciation and amortization and $334K of share-based compensation. Working capital and other items added $25.5M.
Questions
What was Traws Pharma's revenue in the fourth quarter 2024?
Traws Pharma (TRAW) reported revenue of $56K for the fourth quarter 2024 (Q4 2024), 0% from a year earlier and -2% from the quarter before.
Source: Traws Pharma 10-K on SEC EDGAR.